ARCHIVES

Health Reform Bill Contains Unpleasant Surprises For Drug Manufacturers

This article is from The Cancer Letter archive.

Vol. 19 No. 43 | November 5, 1993

Download PDF Visit The Full Archive

Related Articles

Zaltrap Receives Positive Opinion For European Market From CHMP

November 30, 2012

DES-Breast Cancer Risk Studies Concept approved

March 7, 1986

IDMC Halts Mekinist-Tafinlar Trial Early Due to OS Benefit; Recommends Crossover

July 25, 2014

Funding opportunities listed.

May 28, 2004

SBIR Solicitation Issued

September 13, 1996

Review Of Cancer Center supports Grants Needs Refocus On Science, Advisors Say

October 18, 1996